• Filipin III in Advanced Cholesterol Homeostasis Research

  2026-06-22

  Explore how Filipin III, a polyene macrolide antibiotic, powers cutting-edge cholesterol detection in membranes and enables new insights into cholesterol-driven diseases. This article uniquely bridges mechanistic biochemistry with translational applications using Filipin III.

• Early Life Adversity, Oxytocin Signaling, and Defensive Beha

  2026-06-22

  Tan et al. (2026) demonstrate that early life adversity (ELA) impairs innate visually evoked defensive behaviors in mice by disrupting oxytocin receptor signaling in the superior colliculus. This study reveals a previously uncharacterized neurobiological mechanism linking early stress to altered threat responses, with implications for understanding neurodevelopmental and psychiatric vulnerability.

• Remdesivir (GS-5734): Mechanism and Benchmarks in Antiviral

  2026-06-21

  Remdesivir (GS-5734) is a nucleoside analogue prodrug that potently inhibits RNA viruses by targeting viral RNA-dependent RNA polymerase. In cell-based and in vivo models, it demonstrates low EC50 values against coronaviruses and filoviruses, supporting its role as a translational research tool.

• Applied Workflows with Recombinant Human FGF-19 Protein

  2026-06-20

  Leverage the purity and robust bioactivity of Recombinant Human FGF-19 (E.coli, Tag Free, Lyophilized) for precise cell-based metabolic assays and signaling studies. This article details proven setup strategies, protocol enhancements, and troubleshooting tips to maximize reproducibility in FGF-19/FGFR4 pathway research.

• SAR131675: Precision VEGFR-3 Inhibition for Translational Re

  2026-06-19

  This thought-leadership article explores SAR131675’s unique mechanistic profile as a highly selective, ATP-competitive VEGFR-3 inhibitor, situating it at the frontier of lymphangiogenesis and angiogenesis research. Through a synthesis of evidence—including translational applications in oncology, fibrosis, and vascular biology—it provides strategic guidance for researchers designing next-generation studies. The discussion integrates cross-domain relevance, protocol best practices, and an outlook on leveraging SAR131675’s specificity for high-impact preclinical findings, setting a new benchmark beyond conventional product summaries.

• GSK J4 HCl: Selective JMJD3 Inhibitor for Epigenetic Researc

  2026-06-19

  GSK J4 HCl is a potent, cell-permeable JMJD3 inhibitor enabling precise study of histone H3K27 demethylation. It exhibits robust activity in models of inflammation and transcriptional regulation, with validated in vitro and in vivo efficacy. This article details its mechanism, benchmarks, and workflow for advanced epigenetic regulation research.

• CCT007093: Advanced Insights into PPM1D Inhibition and Pyrop

  2026-06-18

  Discover how CCT007093, a selective PPM1D inhibitor, enables precise dissection of p38 MAPK signaling and pyroptosis in disease models. This in-depth analysis reveals novel assay strategies and translational perspectives for cancer and acute kidney injury research.

• Mono-ADP-Ribosylation as a Degradation Signal in PARP7/AHR C

  2026-06-18

  This study uncovers that mono-ADP-ribosylation, catalyzed by PARP7, serves as a direct proteasomal degradation signal for PARP7 itself and the aryl hydrocarbon receptor (AHR). By inhibiting the ubiquitin pathway, the authors reveal a previously hidden post-translational mechanism regulating transcriptional shutdown, with implications for understanding protein turnover and signaling feedback in cancer and cell stress models.

• Imipramine in Autophagy & Apoptosis Workflows: Protocols & I

  2026-06-17

  Imipramine, a tricyclic antidepressant, stands out as a versatile tool for studying autophagy and apoptosis in cancer and neurobiology research. This article details robust workflows, troubleshooting strategies, and practical tips drawn from cutting-edge studies and lipidomics insights.

• TNF-alpha Recombinant Murine Protein in Apoptosis Research

  2026-06-17

  Harnessing the TNF-alpha recombinant murine protein from APExBIO unlocks precise modeling of apoptosis and inflammatory pathways, now with new insights from transcription-independent cell death mechanisms. This guide integrates recent mechanistic discoveries, step-by-step workflows, and practical troubleshooting for reproducible, high-impact cell biology research.

• hiPSC-Derived Intestinal Organoids for Pharmacokinetic Studi

  2026-06-16

  This study introduces a streamlined protocol to derive human intestinal organoids from pluripotent stem cells, improving in vitro modeling of drug metabolism and absorption. The findings support advanced pharmacokinetic assays and address key limitations of conventional cell and animal models.

• WIP1/PPM1D Inhibition Amplifies Pyroptosis via p38 MAPK in A

  2026-06-16

  This study uncovers how WIP1 (PPM1D) phosphatase regulates pyroptosis in sepsis-associated acute kidney injury by modulating the p38 MAPK signaling pathway. Pharmacological inhibition of WIP1 with CCT007093 intensifies p38-driven pyroptotic responses, revealing new mechanistic insight into renal inflammation and repair.

• Functionalized EGCG Nanoparticles Enhance FLASH-RT Efficacy

  2026-06-15

  Xu et al. developed self-assembled EGCG nanoparticles (BENPs) as radiosensitizers to improve the antitumor effects of ultra-high dose rate radiotherapy (FLASH-RT). Their study demonstrates that BENPs amplify DNA damage and stimulate immune responses, resulting in improved tumor control and biosafety, and offers mechanistic insights relevant to cancer therapy optimization.

• WY-14643 (Pirinixic Acid): Advanced Protocols for Metabolic

  2026-06-15

  WY-14643 (Pirinixic Acid) is a benchmark selective PPARα agonist that empowers researchers to dissect metabolic, inflammatory, and regenerative pathways with precision. This guide details robust workflows, troubleshooting strategies, and actionable insights, translating the latest reference study findings into optimized, real-world protocols.

• PCMT1 Drives Ovarian Cancer Metastasis: CRISPR/Cas9 Screen I

  2026-06-14

  Zhang et al. used a genome-wide CRISPR/Cas9 knockout screen to identify PCMT1 as a central regulator of anoikis resistance and metastasis in ovarian cancer. Their findings reveal PCMT1’s role in ECM remodeling and signaling, highlighting it as a potential therapeutic target and providing a foundation for further mechanistic studies.

15451 records 1/1031 page Next 12345 下5页 Last page